These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25591547)

  • 41. Parallel imports and the pricing of pharmaceutical products: evidence from the European Union.
    Ganslandt M; Maskus KE
    J Health Econ; 2004 Sep; 23(5):1035-57. PubMed ID: 15353192
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Veterinary pharmacovigilance. Part 1. The legal basis in the European Union.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):131-47. PubMed ID: 15842304
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Addressing the impact of economic sanctions on Iranian drug shortages in the joint comprehensive plan of action: promoting access to medicines and health diplomacy.
    Setayesh S; Mackey TK
    Global Health; 2016 Jun; 12(1):31. PubMed ID: 27267898
    [TBL] [Abstract][Full Text] [Related]  

  • 44. European prices of newly launched reimbursable pharmaceuticals--a pilot study.
    Martikainen J; Kivi I; Linnosmaa I
    Health Policy; 2005 Nov; 74(3):235-46. PubMed ID: 16226136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes.
    Ioannides-Demos LL; Ibrahim JE; McNeil JJ
    Pharmacoeconomics; 2002; 20(9):577-91. PubMed ID: 12141886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States.
    Vogler S; Habl C; Bogut M; Voncina L
    Croat Med J; 2011 Apr; 52(2):183-97. PubMed ID: 21495202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Generic Drugs in the United States: Policies to Address Pricing and Competition.
    Gupta R; Shah ND; Ross JS
    Clin Pharmacol Ther; 2019 Feb; 105(2):329-337. PubMed ID: 30471089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries.
    Elek P; Takács E; Merész G; Kaló Z
    Health Policy Plan; 2017 Apr; 32(3):349-358. PubMed ID: 27697777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Differences in external price referencing in Europe: a descriptive overview.
    Leopold C; Vogler S; Mantel-Teeuwisse AK; de Joncheere K; Leufkens HG; Laing R
    Health Policy; 2012 Jan; 104(1):50-60. PubMed ID: 22014843
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Drug shortages in the hospital: management, causes and budget impact].
    Claus B; Pauwels K; Baert M; Depoorter J; De Weerdt E; Boussery K; De Spiegeleer B; Commeyne S
    J Pharm Belg; 2015 Mar; (1):24-34. PubMed ID: 26571794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Addressing the Lack of Competition in Generic Drugs to Improve Healthcare Quality and Safety.
    Sivashanker K; Fanikos J; Kachalia A
    J Gen Intern Med; 2018 Nov; 33(11):2005-2007. PubMed ID: 30091120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug shortages in Israel: regulatory perspectives, challenges and solutions.
    Schwartzberg E; Ainbinder D; Vishkauzan A; Gamzu R
    Isr J Health Policy Res; 2017; 6():17. PubMed ID: 28392910
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-cost generic drugs--implications for patients and policymakers.
    Alpern JD; Stauffer WM; Kesselheim AS
    N Engl J Med; 2014 Nov; 371(20):1859-62. PubMed ID: 25390739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The hidden cost of low prices: limited access to new drugs in India.
    Berndt ER; Cockburn IM
    Health Aff (Millwood); 2014 Sep; 33(9):1567-75. PubMed ID: 25201661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Competition in the off-patent medicine market in Spain: The national reference pricing system versus the regional system of tendering for outpatient prescription medicines in Andalusia.
    Casanova-Juanes J; Mestre-Ferrandiz J; Espín-Balbino J
    Health Policy; 2018 Dec; 122(12):1310-1315. PubMed ID: 30389186
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Barriers and facilitators of exploiting the potential of value-added medicines.
    Petykó ZI; Inotai A; Holtorf AP; Brixner D; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun; 20(3):229-236. PubMed ID: 32321326
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Why drug shortages occur.
    Drug Ther Bull; 2015 Mar; 53(3):33-6. PubMed ID: 25765598
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.